FDA Strengthens Warning of Acute Kidney Injury related to Type 2 Diabetes Drugs
August 19, 2016 | Strategic Insights for Ambulatory Care
Preview
The U.S. Food and Drug Administration (FDA) strengthened its existing warning about the risk of acute kidney injury related to the type 2 diabetes medications canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), states a June 14, 2016, FDA safety alert. The agency has received 101 reports of acute kidney injury associated with canagliflozin or dapagliflozin use, some of which required hospitalization and dialysis.